Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4
Abstract
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website .
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (17)
Mary-Ellen Taplin
Dana–Farber Cancer Institute, Boston
Rahul A. Parikh
University of Kansas Medical Center, Westwood, KS
R. Bryan Rumble
Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
Syed Arsalan Ahmed Naqvi
Mayo Clinic, Phoenix, AZ
Fouad Nahhat
1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States
Mariane Fontes Dias
Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Latin America Cooperative Group (LACOG)- Genito-Urinary, Rio de Janeiro, Brazil
Thomas A. Hope
Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
Huan He
National Engineering Laboratory for Druggable Gene and Protein Screening, College of Life Science, Northeast Normal University
Sebastien J. Hotte
McMaster University, Hamilton, Ontario, Canada
Hamid Emamekhoo
M. Hassan Murad
5Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN
Paul Celano
Greater Baltimore Medical Center (GBMC), Towson, MD
Terry M. Kungel
Woolwich, ME
Steve Hentzen
Leawood, KS
Jacob S. Marzalik
JSM Research Services, LLC, Arlington, VA
Michael Thomas Serzan
Dana-Farber Cancer Institute, Boston, MA
Irbaz Bin Riaz
Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA